Escitalopram
Small molecule targets CYP2D6, SLC6A4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | LEXAPRO | — | 2002-08-29 – 2023-05-12 | fda.gov ↗ |
| Approved | US (FDA) | LEXAPRO | — | 2002-08-14 | fda.gov ↗ |
Trials 245 · started per year
Also used as a comparator or background therapy in 205 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03887624 Background | May 2019 → Apr 2021 | major depressive disorder | Zhejiang University | Completed | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT06965569 Background | Apr → Dec 2025 | — | Alar Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06476509 Comparator | May 2024 → Jan 2025 | major depressive disorder | Vigonvita Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT03912974 Comparator | Jul 2019 → Nov 2020 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT02072278 Comparator | Feb → Nov 2014 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT01601730 Comparator | Aug 2010 → Jul 2011 | cocaine abuse, cocaine dependence | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT03274817 Comparator | Jun 2009 → Sep 2019 | Alzheimer disease | NYU Langone Health | Terminated | No outcome recorded |
| Phase 1 | NCT00272025 Comparator | Oct 2006 → Jan 2010 | bipolar depression | Queen's University | Terminated | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04410341 Background | May 2020 → Dec 2024 | major depressive disorder | Sadat City University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03323697 Comparator | Aug 2017 → Sep 2018 | mixed anxiety and depressive disorder | Mazra Mental Health Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT00135421 Comparator | Nov 2005 → Oct 2007 | major depressive disorder | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 219 trials | ||||||
| Phase 2 | NCT06216535 Comparator | May 2025 → Dec 2028 expected | asthma | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06828887 Comparator | Apr 2025 → Sep 2026 expected | major depressive disorder | Vigonvita Life Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT03429075 Comparator | Jan 2019 → Apr 2020 | major depressive disorder | Imperial College London | Completed | No outcome recorded |
| Phase 2 | NCT03388164 Comparator | Jan 2018 → May 2019 | depressive disorder | Laureate Institute for Brain Research, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03321526 Background | Dec 2017 → Jun 2019 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02407821 Comparator | Mar 2015 → Jan 2017 | end stage renal failure | University Health Network, Toronto | Terminated | No outcome recorded |
| Phase 2 | NCT02469545 Comparator | Jun 2014 → Mar 2016 | anxiety disorder, major depressive disorder | Medical University of Bialystok | Completed | No outcome recorded |
| Phase 2 | NCT01741142 Comparator | Jan 2012 → Oct 2013 | major depressive disorder | AbbVie | Terminated | No outcome recorded |
| Phase 2 | NCT01369095 Comparator | Jul 2011 → May 2013 | depressive disorder | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01435759 Background | May 2011 → Jan 2014 | major depressive disorder | Shire | Completed | No outcome recorded |
| Phase 2 | NCT01034995 Comparator | Feb 2010 → Mar 2011 | major depressive disorder | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01020799 Comparator | Nov 2009 → Apr 2010 | major depressive disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00905424 Comparator | Jul 2009 → Aug 2010 | major depressive disorder | Shire | Completed | No outcome recorded |
| Phase 2 | NCT00854100 Background | Jun 2009 → Dec 2010 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 2 | NCT00797966 Background | May 2009 → Jun 2010 | major depressive disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00822744 Comparator | Dec 2008 → Feb 2010 | major depressive disorder | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00485888 Comparator | Oct 2008 → Aug 2013 | social phobia | START Clinic for Mood and Anxiety Disorders | Completed | No outcome recorded |
| Phase 2 | NCT00566202 Comparator | Dec 2007 → Dec 2008 | major depressive disorder | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 2 | NCT00420004 Comparator | Dec 2006 → Mar 2008 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT03909217 Comparator | Jul 2019 → Jul 2021 | major depressive disorder | The University of Hong Kong | Completed | No outcome recorded |
| Phase 2/3 | NCT02674529 Comparator | Sep 2016 → May 2021 | major depressive disorder | Marta Peciña, MD PhD | Completed | No outcome recorded |
| Phase 2/3 | NCT01219686 Comparator | Oct 2010 → Apr 2013 | major depressive disorder | Markus KOSEL | Terminated | No outcome recorded |
| Phase 2/3 | NCT00481325 Comparator | Jul 2007 → Mar 2008 | generalized anxiety disorder | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2/3 | NCT00248651 Comparator | Oct 2006 → Jul 2013 | dyspepsia | Mayo Clinic | Completed | No outcome recorded |
| Phase 2/3 | NCT00133276 Comparator | Aug 2005 → Jun 2008 | hepatitis C virus infection | Foundation for Liver Research | Completed | No outcome recorded |
| Phase 2/3 | NCT00070941 Comparator | Jul 2003 → Jun 2010 | Parkinson disease, depressive disorder | NYU Langone Health | Completed | No outcome recorded |
| Phase 344 trials | ||||||
| Phase 3 | NCT06025474 Comparator | Jan → Oct 2023 | burning mouth syndrome | Federico II University | Unknown | No outcome recorded |
| Phase 3 | NCT04973930 Comparator | Mar 2022 → Dec 2025 | breast cancer, major depressive disorder | New York State Psychiatric Institute | Suspended | No outcome recorded |
| Phase 3 | NCT04763135 Comparator | Dec 2021 | cancer, metastatic neoplasm | Hospices Civils de Lyon | Terminated | No outcome recorded |
| Phase 3 | NCT03652870 Comparator | Mar 2021 → Jan 2023 | Parkinson disease, depressive disorder | University College, London | Completed | No outcome recorded |
| Phase 3 | NCT04598230 Comparator | Feb 2021 → Aug 2025 overdue | generalized anxiety disorder, separation anxiety disorder, social phobia | Ann & Robert H Lurie Children's Hospital of Chicago | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04476030 Background | Nov 2020 → Oct 2021 | major depressive disorder | Biogen | Completed | No outcome recorded |
| Phase 3 | NCT04162522 Comparator | Dec 2019 → Dec 2022 | major depressive disorder | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 3 | NCT03852160 Background | Dec 2019 → Jul 2021 | major depressive disorder | Janssen-Cilag International NV | Withdrawn | No outcome recorded |
| Phase 3 | NCT03538691 Background | Jul 2018 → Jul 2022 | major depressive disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03434041 Background | May 2018 → Apr 2021 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02493868 Background | Oct 2015 → Feb 2018 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02497287 Background | Sep 2015 → Oct 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02624102 Background | Sep 2015 → Dec 2017 | major depressive disorder | Hemanny, Curt, M.D. | Completed | No outcome recorded |
| Phase 3 | NCT02422186 Background | Aug 2015 → Aug 2017 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02417064 Background | Aug 2015 → Feb 2018 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02418585 Background | Aug 2015 → Jun 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02191397 Comparator | Feb 2015 → Oct 2016 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02272517 Comparator | Dec 2014 → Mar 2016 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT02279953 Background | Oct 2014 → Apr 2016 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT01894815 Comparator | Oct 2013 → Jul 2016 | major depressive disorder | University of Sao Paulo | Completed | No outcome recorded |
| Phase 3 | NCT01838681 Background | Jun 2013 → Jun 2016 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT01838876 Background | Apr 2013 → Jul 2015 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT01715805 Background | Nov 2012 → Jun 2016 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT01655706 Comparator | Apr 2012 → Jan 2017 | major depressive disorder | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 3 | NCT01436175 Background | Feb 2012 → Mar 2014 | major depressive disorder | Shire | Terminated | No outcome recorded |
| Phase 3 | NCT01436162 Background | Oct 2011 → Dec 2013 | major depressive disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT01360866 Background | Oct 2011 → Apr 2017 | major depressive disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01364649 Comparator | Jun 2011 → Dec 2013 | — | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00958633 Comparator | Nov 2010 → Mar 2020 | bipolar I disorder | University of British Columbia | Terminated | No outcome recorded |
| Phase 3 | NCT01363310 Comparator | Oct 2010 → Jan 2013 | major depressive disorder | Physicians Research And Education Network | Terminated | No outcome recorded |
| Phase 3 | NCT01111552 Comparator | Jul 2010 → Sep 2011 | major depressive disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00953108 Comparator | Sep 2009 → Feb 2012 | major depressive disorder | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 3 | NCT00531622 Background | Sep 2007 → Jan 2009 | major depressive disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00642694 Background | May 2007 → May 2010 | insomnia, major depressive disorder | University of Texas Southwestern Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT00432614 Background | Jan 2007 → Feb 2008 | major depressive disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00415142 Comparator | Dec 2006 → Feb 2008 | depressive disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00406640 Comparator | Dec 2006 → Feb 2008 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00475878 Comparator | Dec 2006 → Sep 2009 | depressive disorder, opiate dependence | Butler Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00417118 Comparator | Dec 2006 → Apr 2008 | generalized anxiety disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00351910 Background | May 2006 → Apr 2007 | major depressive disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00190333 Comparator | Jun 2005 → Dec 2008 | pulmonary hypertension | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT00136318 Comparator | Jan 2004 → Sep 2008 | depressive disorder | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 3 | NCT00074815 Background | Sep 2003 → Nov 2009 | obsessive-compulsive disorder | Duke University | Completed | No outcome recorded |
| Phase 3 | NCT00935675 Comparator | — | carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Unknown | No outcome recorded |
| Phase 471 trials | ||||||
| Phase 4 | NCT07478796 Comparator | Apr 2025 → Nov 2027 expected | major depressive disorder | Poznan University of Medical Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT05737511 Comparator | Dec 2023 → Dec 2026 expected | panic disorder | Sultan Qaboos University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07590609 Background | May 2023 → Jan 2026 | major depressive disorder | Peking University Sixth Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05017311 Comparator | Jan 2023 → Dec 2028 expected | major depressive disorder | Nova Scotia Health Authority | Recruiting | No outcome recorded |
| Phase 4 | NCT06675851 Comparator | Dec 2022 → Dec 2026 expected | major depressive disorder | Medical University of Vienna | Recruiting | No outcome recorded |
| Phase 4 | NCT07628153 Comparator | Jul 2022 → Feb 2025 | anxiety disorder | I.M. Sechenov First Moscow State Medical University | Completed | No outcome recorded |
| Phase 4 | NCT05004987 Comparator | Feb 2022 → Dec 2026 expected | Alzheimer disease, major depressive disorder | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 4 | NCT04388202 Comparator | Oct 2020 → May 2023 | major depressive disorder | Alto Neuroscience | Withdrawn | No outcome recorded |
| Phase 4 | NCT04352101 Comparator | Sep 2020 → Jul 2022 | major depressive disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT04245748 Comparator | Mar 2020 → Jul 2025 overdue | mixed anxiety and depressive disorder | University of Cincinnati | Recruiting | No outcome recorded |
| Phase 4 | NCT04245436 Comparator | Jan 2020 → Jul 2025 overdue | anxiety, depressive disorder | University of Cincinnati | Recruiting | No outcome recorded |
| Phase 4 | NCT05148169 Background | Jan 2020 → Dec 2022 | major depressive disorder | Shanghai Mental Health Center | Unknown | No outcome recorded |
| Phase 4 | NCT03779789 Comparator | Feb 2019 → Feb 2023 | major depressive disorder | Azienda Ospedaliera Universitaria Integrata Verona | Completed | No outcome recorded |
| Phase 4 | NCT03812588 Comparator | Jan 2019 → May 2020 | major depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT03522844 Comparator | Jun 2018 → Oct 2021 | agoraphobia, generalized anxiety disorder, panic disorder, social phobia | Georgetown University | Completed | No outcome recorded |
| Phase 4 | NCT03321006 Comparator | May 2018 → May 2021 | depressive disorder, hearing loss disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT04543123 Background | Nov 2017 → May 2019 | major depressive disorder | Jeong-Ho Chae | Completed | No outcome recorded |
| Phase 4 | NCT03122158 Comparator | Apr 2017 → Sep 2018 | anxiety disorder, major depressive disorder | Erzurum Regional Training & Research Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03131050 Background | Mar 2017 → Feb 2018 | major depressive disorder | Capital Medical University | Completed | No outcome recorded |
| Phase 4 | NCT03187093 Comparator | Oct 2016 → Apr 2019 | major depressive disorder | Oleg Levada | Unknown | No outcome recorded |
| Phase 4 | NCT02623205 Comparator | May 2015 → Mar 2020 | depressive disorder | Stony Brook University | Completed | No outcome recorded |
| Phase 4 | NCT02332291 Comparator | Apr 2015 → Aug 2020 | major depressive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02137369 Comparator | Sep 2014 → Oct 2019 | major depressive disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT01483053 Comparator | Jan 2014 → Feb 2015 | major depressive disorder | Baker Heart and Diabetes Institute | Unknown | No outcome recorded |
| Phase 4 | NCT01903447 Comparator | Dec 2013 → Feb 2018 | anxiety | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 4 | NCT01902004 Comparator | Oct 2013 → Jan 2019 | cognitive disorder, depressive disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT05840692 Comparator | Aug 2013 → Oct 2017 | polycystic ovary syndrome | Odense University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01961180 Comparator | Jun 2013 → Jul 2015 | polycystic ovary syndrome | Odense University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02082392 Comparator | Sep 2012 → Aug 2015 | major depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT01368068 Comparator | Jul 2012 | — | The Alfred | Terminated | No outcome recorded |
| Phase 4 | NCT01764867 Comparator | Jun 2012 → Oct 2014 | major depressive disorder | Shanghai Mental Health Center | Unknown | No outcome recorded |
| Phase 4 | NCT01551225 Comparator | Jan 2012 → Sep 2016 | irritable bowel syndrome, panic disorder | Maastricht University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01460212 Comparator | Dec 2011 → Dec 2014 | major depressive disorder | Nanjing Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT01477203 Comparator | Nov 2011 → Sep 2016 | anxiety disorder, major depressive disorder | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01430520 Comparator | Sep 2011 → Apr 2013 | — | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01357967 Comparator | May 2011 → Dec 2012 | major depressive disorder | Inje University | Unknown | No outcome recorded |
| Phase 4 | NCT01479829 Background | Mar 2011 → Dec 2017 | bipolar depression | Loyola University | Completed | No outcome recorded |
| Phase 4 | NCT01309776 Comparator | Mar 2011 → Sep 2012 | major depressive disorder | Samsung Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01324700 Comparator | Jul 2010 → May 2015 | asthma, depressive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01101685 Comparator | Feb 2010 → Mar 2011 | depressive disorder | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT01082237 Comparator | Oct 2009 → Oct 2012 | major depressive disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT00985504 Comparator | Sep 2009 → Dec 2010 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01305707 Comparator | Jul 2009 → Jul 2014 | major depressive disorder | Hospital Universitari de Bellvitge | Terminated | No outcome recorded |
| Phase 4 | NCT00917059 Comparator | May 2009 → May 2012 | depressive disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT00926835 Comparator | May 2009 → May 2015 | major depressive disorder | Ministry of Health & Welfare, Korea | Terminated | No outcome recorded |
| Phase 4 | NCT00754793 Comparator | Jan 2009 → Aug 2010 | chronic rhinosinusitis, major depressive disorder, neurological pain disorder | University of Washington | Terminated | No outcome recorded |
| Phase 4 | NCT00723060 Comparator | Sep 2008 → Jan 2011 | obsessive-compulsive disorder | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00693849 Comparator | Sep 2008 → Dec 2019 | major depressive disorder | BRC Operations Pty. Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT00955474 Comparator | Sep 2008 → Jan 2013 | major depressive disorder | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00594269 Comparator | Aug 2008 → Dec 2010 | dementia | Innlandet Hospital Trust | Completed | No outcome recorded |
| Phase 4 | NCT00824044 Comparator | Jul 2008 → Mar 2011 | major depressive disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01271244 Comparator | Jun 2008 → Jun 2013 | post-traumatic stress disorder | VA Nebraska Western Iowa Health Care System | Completed | No outcome recorded |
| Phase 4 | NCT00628914 Background | May 2008 → Nov 2009 | insomnia, major depressive disorder | University of California, Los Angeles | Unknown | No outcome recorded |
| Phase 4 | NCT01119638 Comparator | Apr 2008 → Apr 2010 | Alzheimer disease, psychotic disorder | Abarbanel Mental Health Center | Completed | No outcome recorded |
| Phase 4 | NCT00590863 Comparator | Mar 2008 → Sep 2009 | major depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT00621946 Comparator | Mar 2008 → Mar 2010 | asthma, major depressive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01797380 Comparator | Jan 2008 → Apr 2009 | HIV infectious disease, depressive disorder | Duke University | Terminated | No outcome recorded |
| Phase 4 | NCT00519428 Comparator | Aug 2007 → Jul 2011 | major depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT00826111 Comparator | Aug 2007 → Jan 2011 | anxiety, depressive disorder, insomnia | Steward St. Elizabeth's Medical Center of Boston, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00825825 Comparator | May 2007 → Apr 2011 | — | Michael Henry, MD | Completed | No outcome recorded |
| Phase 4 | NCT00386841 Comparator | Apr 2007 → Jun 2009 | — | University of Copenhagen | Completed | No outcome recorded |
| Phase 4 | NCT00452543 Background | Mar 2007 → May 2010 | alcohol abuse, alcohol dependence, major depressive disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00813735 Background | Sep 2006 → Mar 2009 | insomnia | Lehigh Center for Clinical Research | Completed | No outcome recorded |
| Phase 4 | NCT00243477 Comparator | Jan 2006 → Feb 2011 | coronary artery disorder | Hopital Jean Minjoz | Completed | No outcome recorded |
| Phase 4 | NCT00200902 Comparator | Aug 2005 → Jun 2009 | depressive disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT00375843 Comparator | Jan 2005 → Jun 2007 | depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT00177294 Background | Apr 2004 → Aug 2009 | major depressive disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00177671 Background | Dec 2003 → Sep 2009 | dementia, major depressive disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00423969 Background | Nov 2003 → Sep 2005 | depressive disorder | Indiana University | Terminated | No outcome recorded |
| Phase 4 | NCT00166114 Comparator | Feb 2002 → Jan 2009 | major depressive disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT01561092 Comparator | — | stroke disorder | University of Aarhus | Withdrawn | No outcome recorded |
| Phase not applicable53 trials | ||||||
| — | NCT07331987 Background | Jun → Dec 2026 expected | mixed anxiety and depressive disorder | Moon (Guangzhou) Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| — | NCT07645807 Background | Jun 2026 → Jan 2027 expected | — | Sichuan Credit Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| — | NCT06937476 Background | May 2025 → Apr 2026 overdue | major depressive disorder, rumination disorder | Central South University | Active not recruiting | No outcome recorded |
| — | NCT06957223 Comparator | May → Nov 2025 | major depressive disorder | Asad Ullah Jan | Completed | No outcome recorded |
| — | NCT07025590 Comparator | Apr 2025 → Dec 2026 expected | cardiovascular disorder, mixed anxiety and depressive disorder | Guangdong Provincial People's Hospital | Recruiting | No outcome recorded |
| — | NCT06692361 Background | Jan 2025 → Jun 2026 overdue | major depressive disorder | Gang Wang | Recruiting | No outcome recorded |
| — | NCT06545474 Comparator | Sep 2024 → Dec 2026 expected | major depressive disorder | University Hospital Tuebingen | Not yet recruiting | No outcome recorded |
| — | NCT06266715 Background | Mar 2024 → Dec 2026 expected | depressive disorder | Nanfang Hospital, Southern Medical University | Recruiting | No outcome recorded |
| — | NCT05818735 Comparator | Dec 2023 → Dec 2025 | depressive disorder | Shanghai Municipal Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
| — | NCT06358014 Background | May 2023 → Dec 2024 | depressive disorder | Xiao Wang | Unknown | No outcome recorded |
| — | NCT05945342 Comparator | Jan 2023 → Dec 2024 | depressive disorder | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| — | NCT05528224 Background | Sep 2022 → Aug 2023 | obsessive-compulsive disorder | Shanghai Mental Health Center | Terminated | No outcome recorded |
| — | NCT06054321 Comparator | Aug 2022 → Dec 2028 expected | major depressive disorder | Chonnam National University Hospital | Recruiting | No outcome recorded |
| — | NCT06325605 Comparator | Mar → Oct 2022 | — | Zhen-Hong Hu | Completed | No outcome recorded |
| — | NCT04977232 Background | Sep 2021 → Dec 2022 | depressive disorder | Central South University | Completed | No outcome recorded |
| — | NCT05588102 Background | May 2021 → May 2023 | cognitive disorder | Capital Medical University | Completed | No outcome recorded |
| — | NCT06758167 Background | Nov 2020 → Apr 2024 | major depressive disorder | Peking University Sixth Hospital | Completed | No outcome recorded |
| — | NCT04156425 Background | Jul 2020 → Dec 2024 | major depressive disorder | Shanghai Mental Health Center | Unknown | No outcome recorded |
| — | NCT07077291 Background | Feb 2020 → May 2022 | major depressive disorder | Yun Zhang | Completed | No outcome recorded |
| — | NCT04344678 Background | Jan 2020 → Oct 2024 | major depressive disorder | Sadat City University | Withdrawn | No outcome recorded |
| — | NCT04069819 Background | Aug 2019 → Dec 2021 | major depressive disorder | Sadat City University | Completed | No outcome recorded |
| — | NCT04037111 Background | Jul 2019 → Jan 2021 | major depressive disorder, rheumatoid arthritis | Xijing Hospital | Unknown | No outcome recorded |
| — | NCT03899194 Comparator | Jan 2019 → Dec 2021 | major depressive disorder | Shanghai Mental Health Center | Unknown | No outcome recorded |
| — | NCT03346239 Comparator | Jul 2018 → Dec 2021 | social phobia | Tel Aviv University | Completed | No outcome recorded |
| — | NCT03558256 Background | May 2016 → Dec 2018 | major depressive disorder | Shanghai Mental Health Center | Unknown | No outcome recorded |
| — | NCT02579343 Comparator | Aug 2015 → May 2016 | major depressive disorder | Florida Gulf Coast University | Completed | No outcome recorded |
| — | NCT03554447 Background | Apr 2015 → Dec 2017 | major depressive disorder | Mahmoud Samy Abdallah | Completed | No outcome recorded |
| — | NCT01931202 Comparator | Feb 2014 → Jan 2019 | major depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| — | NCT02423694 Comparator | Sep 2013 → Dec 2015 | depressive disorder, premature menopause | Guangdong Provincial Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
| — | NCT01944657 Comparator | Sep 2013 → Dec 2015 | major depressive disorder | Sheppard Pratt Health System | Withdrawn | No outcome recorded |
| — | NCT01896349 Background | Apr 2013 → Aug 2014 | — | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| — | NCT01962753 Background | May 2012 → Jan 2020 | major depressive disorder | University Hospital, Tours | Completed | No outcome recorded |
| — | NCT01538693 Comparator | Dec 2011 → May 2015 | spinal cord injury | T. George Hornby | Completed | No outcome recorded |
| — | NCT01488266 Comparator | Nov 2011 → Jan 2013 | major depressive disorder | Korea University | Unknown | No outcome recorded |
| — | NCT01831440 Background | Jan 2011 → Jan 2014 | depressive disorder | Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT02480400 Comparator | Jun 2010 → Jun 2012 | major depressive disorder | Abarbanel Mental Health Center | Completed | No outcome recorded |
| — | NCT00989053 Comparator | Jan 2010 → Jan 2012 | anxiety, depressive disorder | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| — | NCT00894543 Comparator | Jul 2009 → Jun 2010 | — | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| — | NCT00944996 Comparator | Jun 2009 → Jun 2010 | major depressive disorder | Tirat Carmel Mental Health Center | Completed | No outcome recorded |
| — | NCT00953745 Comparator | May 2009 → Jun 2012 | major depressive disorder | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT00971815 Comparator | May 2009 → Sep 2011 | anxiety disorder, cardiovascular disorder, fetal growth restriction, melancholia +1 | University of Aarhus | Completed | No outcome recorded |
| — | NCT01404871 Comparator | Apr 2009 → Oct 2011 | obsessive-compulsive disorder | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| — | NCT00746239 Comparator | Aug 2008 → Jul 2010 | insomnia, panic disorder | Milton S. Hershey Medical Center | Terminated | No outcome recorded |
| — | NCT00620789 Comparator | Mar 2008 → Jan 2014 | insomnia, major depressive disorder | Toronto Metropolitan University | Unknown | No outcome recorded |
| — | NCT00564278 Background | Feb 2008 → Aug 2013 | depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| — | NCT00598052 Comparator | Dec 2007 → Oct 2008 | cannabis dependence | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| — | NCT00517764 Comparator | Dec 2006 → Jun 2013 | depressive disorder | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| — | NCT00360399 Comparator | Aug 2006 → Apr 2015 | major depressive disorder | Emory University | Completed | No outcome recorded |
| — | NCT00416221 Background | Apr 2006 → Jan 2007 | depressive disorder | University of California, San Diego | Completed | No outcome recorded |
| — | NCT00295347 Background | Dec 2005 → Jun 2008 | major depressive disorder | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
| — | NCT00300313 Comparator | Jun 2005 → May 2009 | post-traumatic stress disorder | Sheba Medical Center | Completed | No outcome recorded |
| — | NCT00101452 Comparator | Apr 2005 → Jun 2010 | major depressive disorder | Maurizio Fava, MD | Completed | No outcome recorded |
| — | NCT00206934 Comparator | Mar 2005 → Mar 2006 | — | University of Copenhagen | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-06-18 | Takeda | Results of a New Study of Brintellix ® (vortioxetine) vs. Escitalopram on Sexual Functioning in Well Treated MDD Patients Experiencing Treatment-Emergent Sexual Dysfunction takeda.com ↗ |
| 2012-03-14 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of Generic Lexapro® in the United States; Awarded 180-Day Period of Marketing Exclusivity tevapharm.com ↗ |
| 2006-05-22 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval of Generic Lexapro® Tablets tevapharm.com ↗ |
Evidence & citations 27 cited values
Every value below carries the sentence it was read from. 456 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | escitalopram | “The proposed study will consist of a double-blinded, randomized controlled trial using a crossover design to assess the effects of SSRIs (escitalopram oxalate, Lexapro®, Forest...” NCT01788969 ↗434“we have restricted the IMPACT list of antidepressants to SSRIs (sertraline, escitalopram, paroxetine, fluoxetine, citalopram), duloxetine, bupropion, and mirtazapine. These...” NCT02458690 ↗ “Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa)...” NCT01831440 ↗ “Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278 ↗ “Medication group is a control group that can choose to use the serotonin reuptake inhibitors (SSRIs) approved by China food and Drug Administration (SFDA) for the treatment of...” NCT03558256 ↗ “In cases of intolerance or adverse reaction to fluoxetine, the investigator will switch to sertraline (25 to 200mg) or escitalopram (5 to 20mg), the other two antidepressants...” NCT05002309 ↗ “ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its...” NCT01838876 ↗ “Eligible adults (18-65 years) were assigned to antidepressant monotherapy (escitalopram or venlafaxine extended-release) plus lisdexamfetamine dimesylate-matching placebo...” PMID 28857719 ↗ Aug 2017 “SSRI (paxil CR, es-citalopram, fluoxetine, sertraline) start with (paxil CR 12.5mg, es-citalopram 10mg, fluoxetine 20mg, sertraline 50mg) for 1 week up to maximal dosage,...” NCT01357967 ↗ “Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week...” NCT00854100 ↗ “Selective Serotonin Reuptake Inhibitor (Escitalopram, 5-10 mg in pregnancy and Sertraline, 12.5-25 mg in postpartum) and/or Benzodiazepine (Alprazolam, 0.25-0.5 mg) will be...” NCT06001021 ↗ “SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine...” NCT01436175 ↗ “The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for...” NCT05148169 ↗ “Participants will receive SSRI antidepressant (such as, citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline, vilazodone or vortioxetine) as a part of...” NCT03321526 ↗ “If never taken SSRI or SNRI, commence primary medication arm (SSRI: sertraline, escitalopram or Pregabalin/SNRI: duloxetine, venlafaxine) will be described to patient and will...” NCT04478526 ↗ “Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.” NCT00742573 ↗ “approved by the State Food and Drug Administration (CFDA) for the treatment of OCD (i.e., fluoxetine, paroxetine, sertraline and fluvoxamine) as well as citalopram and escitalopram” NCT05528224 ↗ “This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram, with no specific restrictions on the type of drugs.” NCT06358014 ↗ “Patients assigned to the low expectancy condition will be told they will receive either placebo or escitalopram when in fact they will receive escitalopram for eight weeks.” NCT04836533 ↗ “We made other SSRIs (escitalopram, sertraline) and SNRIs (desvenlafaxine, duloxetine, venlafaxine) our third-line antidepressants, given their negligible effects on weight.” NCT04437485 ↗ “ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.” NCT01715805 ↗ “Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily” NCT01436162 ↗ “If patient has a history of non-response or cannot tolerate escitalopram and/or duloxetine, then they will be treated openly with an approved antidepressant.” NCT01973283 ↗ “Patients were assessed before and 5 hours after single-dose, overencapsulated 10-mg doses of escitalopram (SSRI) or placebo, with 1 week between conditions.” PMID 26376447 ↗ Sep 2015 “Throughout the study, all subjects will receive either escitalopram (Lexapro) or citalopram (Celexa) on the basis of the study doctor's clinical judgment.” NCT00361218 ↗ “Preliminary data indicate that a single dose of the SSRI Escitalopram is sufficient to induce LTP-like effects in the motor cortex of healthy volunteers” NCT02865642 ↗ “All of the participants will take 10 mg of oral escitalopram daily for 4 weeks, with flexible adjustment thereafter based on clinical response.” PMID 40876882 ↗ Aug 2025 “The investigators will use the SSRI escitalopram (Lexapro), which has received FDA approval for the treatment of anxiety, in 5 mg capsules.” NCT02516332 ↗ “Subjects eligible to participate in the study will receive IM saline and will use escitalopram 15 mg and aripiprazole 5 mg as randomized” NCT04234776 ↗ “primary focus will be on serotonin-reuptake inhibiting antidepressant (escitalopram 5-20mg, sertraline 50-200 mg daily) monotherapy” NCT02752542 ↗ “Medication will begin with 10mg escitalopram daily (or its equivalent), increased to 30 mg/day (or its equivalent) by week 6” NCT00787501 ↗ “Patients with MDD, in use of antidepressants (fluoxetine, citalopram, escitalopram, bupropion, etc.) without psychotherapy.” NCT02624102 ↗ “This arm will receive treatment with the chemical neuromodulator escitalopram (Lexapro) at 10 mg once per day for 8 weeks.” NCT05519683 ↗ “medication treatment will be a selective serotonin reuptake inhibitor (either fluoxetine, sertraline or escitalopram).” NCT04598230 ↗ “selective serotonin reuptake inhibitors (fluoxetine, sertraline, citalopram, escitalopram, paroxetine or fluvoxamine)” NCT03993535 ↗ “Escitalopram oxalate (antidepressant) 20 mg/day oral + 20, 30, or 50 mg SPD489 oral once daily for 6 weeks” NCT00905424 ↗ “Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label” NCT01838681 ↗ “Escitalopram, a highly selective serotonin reuptake inhibitor, is usually effective for panic dis order” NCT00767871 ↗ “sertraline: 100-200mg, citalopram 20-40mg, escitalopram 10-20mg, paroxetine 20-60mg; fluoxetine 20-80mg” NCT01903447 ↗ “Escitalopram oxalate tablets should be taken orally once every morning for 2 months, each time 10-20mg” NCT04037111 ↗ “Subjects receive 10 mg escitalopram daily for four weeks and 10 or 20 mg for an additional six weeks.” NCT00826111 ↗ “After completion of imaging procedures, patients will receive treatment with escitalopram 10-20mg.” NCT02711215 ↗ “AD: aripiprazole, bupropion, duloxetine, escitalopram, mirtazapine, sertraline, venlafaxine” NCT04747314 ↗ “Participants receive 4 weeks SSRI treatment with escitalopram (10mg/day) as standard drug.” NCT06545474 ↗ “which included escitalopram, sertraline, and desvenlafaxine in a prescribed sequence.” PMID 27788313 ↗ Oct 2016 “Participants will take escitalopram (10 - 20 mg/day)+ placebo (1 to 3 pills per day).” NCT00590863 ↗ “fluoxetine, paroxetine, sertraline, fluvoxamine, escitalopram, clomipramine” NCT02431845 ↗ “Patients who cannot tolerate fluoxetine will be switched to escitalopram.” NCT06153004 ↗ “Escitalopram, 20mg-40mg daily or Sertraline 50-150 mg daily for 12 weeks” NCT02137369 ↗ “Escitalopram (SCIT) is frequently prescribed to breastfeeding women.” PMID 32162723 ↗ Apr 2020 “Escitalopram will similarly be dosed between 5 mg and 30 mg daily.” NCT04973930 ↗ “Participants will receive outpatient treatment with escitalopram.” NCT07488910 ↗ “Fluoxetine, escitalopram, citalopram, fluvoxamine, or sertraline” NCT03222570 ↗ “the other receiving an SSRI (e.g., sertraline or escitalopram)” NCT06957223 ↗ “paroxetine, fluoxetine, sertraline, escitalopram, citalopram” NCT00944996 ↗ “Escitalopram 20 mg tablet plus one placebo tablet” NCT04344678 ↗ “antidepressant monotherapy(escitalopram) group” NCT06054321 ↗ “escitalopram 10mg once daily for 3 months” NCT00902421 ↗ “escitalopram, citalopram or sertraline” NCT02279953 ↗ “- Escitalopram 10-20 mg/d. N06AB10” NCT01305707 ↗ “escitalopram (Lexapro and others)” NCT01944657 ↗ “escitalopram (Lexapro®) tablets” NCT03538691 ↗ “Escitalopram (Lexapro)5-30;” NCT00074815 ↗ “escitalopram 10-20mg/day” NCT02023567 ↗ “escitalopram (Lexapro)” NCT01460212 ↗ “Escitalopram (Lexapro)” NCT00797966 ↗ “Escitalopram, Lexapro” NCT01916824 ↗ “escitalopram” NCT00157547 ↗ “escitalopram” NCT01488266 ↗ |
| Known as | Cipralex | “The aim of this study is to evaluate the therapeutic effect of escitalopram (cipralex) in the treatment of negative symptoms in schizophrenic patients receiving either typical...” NCT00148447 ↗7“The purpose of the study is to evaluate tolerability and efficacy of escitalopram (Cipralex) treatment in doses beyond 20mg (20-40 mg/d) in patients with OCD and schizophrenia,...” NCT00708396 ↗ “Cipralex (escitalopram)” NCT00368862 ↗ “Cipralex (escitalopram)” NCT06675851 ↗ |
| Known as | ESC | “BACKGROUND: In this study, the impact of quetiapine fumarate extended release (QXR) and escitalopram (ESC) on HPA axis activity was investigated in depressed patients in...” PMID 24275013 ↗ Oct 20135“In our experience, venlafaxine (VLX) and escitalopram (ESC) are the two antidepressants best tolerated and least likely to interfere with oncotherapy for patients with MDD and...” NCT04973930 ↗ “escitalopram (ESC) added a second phase using a synchronous, videoconference (VC) format” PMID 40324655 ↗ May 2025 “initially treated with a combination of escitalopram (ESC) plus bupropion (BUP)” PMID 19820552 ↗ Sep 2009 “plus escitalopram (ESC) 20 mg once daily for six weeks” PMID 34545997 ↗ Sep 2021 “in combination with escitalopram (ESC).” PMID 31630035 ↗ Oct 2019 |
| Known as | Escitalopram (as oxalate) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1508 ↗ |
| Known as | Escitalopram 20 mg (Lexapro, Tablet) | “Escitalopram 20 mg (Lexapro, Tablet)” NCT01871701 ↗ |
| Known as | Escitalopram = Cipralex/Lexapro/Seroplex/Sipralexa | “Escitalopram = Cipralex/Lexapro/Seroplex/Sipralexa” NCT00807248 ↗ |
| Known as | escitalopram = Lexapro | “escitalopram = Lexapro” NCT00296712 ↗3“Escitalopram (Lexapro)” NCT00610506 ↗ “escitalopram (Lexapro)” NCT01460212 ↗ “Escitalopram, Lexapro” NCT01916824 ↗ |
| Known as | Escitalopram Oxalate | “The proposed study will consist of a double-blinded, randomized controlled trial using a crossover design to assess the effects of SSRIs (escitalopram oxalate, Lexapro®, Forest...” NCT01788969 ↗10“For women, a pregnancy test will also be administered no more than 48 hours before SPECT-CT imaging and the beginning of escitalopram oxalate (Lexapro) treatment.” NCT01401595 ↗ “Escitalopram oxalate (antidepressant) 20 mg/day oral + 20, 30, or 50 mg SPD489 oral once daily for 6 weeks” NCT00905424 ↗ “Escitalopram oxalate (Reconter), 10mg/day (first 3 weeks) and 20mg/day (week 3 to week 10).” NCT01894815 ↗ “escitalopram oxalate , a selective-5HT reuptake inhibitor (SSRI)” NCT01538693 ↗ “in Depressed Patients on Escitalopram Oxalate (Lexapro)” NCT00416221 ↗ “Escitalopram (as escitalopram oxalate) tablet” NCT07645807 ↗ “Escitalopram Oxalate Tablets 20 mg” NCT00648661 ↗ “Escitalopram oxalate tablets” NCT06680531 ↗ “Drug: Escitalopram Oxalate” NCT05004987 ↗ |
| Known as | escitalopram/Cipralex | “escitalopram/Cipralex” NCT01219686 ↗ |
| Known as | ESERTIA | ChEMBL registry synonym — accepted as the source's own label CHEMBL1508 ↗ |
| Known as | ESITOL | ChEMBL registry synonym — accepted as the source's own label CHEMBL1508 ↗ |
| Known as | Innovator Escitalopram | “fixed dose(generic escitalopram 10mg/d or Innovator Escitalopram(Lexapro®) 10mg/d)” NCT00866593 ↗ |
| Known as | Lexapro | “The proposed study will consist of a double-blinded, randomized controlled trial using a crossover design to assess the effects of SSRIs (escitalopram oxalate, Lexapro®, Forest...” NCT01788969 ↗29“Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa)...” NCT01831440 ↗ “Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278 ↗ “The goal of this clinical trial is to evaluate the acute effects of escitalopram (Lexapro®) on select brain networks during task-based functional magnetic resonance imaging...” NCT06826326 ↗ “The purpose of the study is to evaluate the efficacy and safety of flexible doses of escitalopram (Lexapro) compared to sertraline (Zoloft) for treatment of Dysthymic Disorder.” NCT00234312 ↗ “Throughout the study, all subjects will receive either escitalopram (Lexapro) or citalopram (Celexa) on the basis of the study doctor's clinical judgment.” NCT00361218 ↗ “This study compares the effectiveness of the combination of antidepressants: Lexapro and Pramipexole, with the effectiveness of each antidepressant alone.” NCT00086307 ↗ “The investigators will use the SSRI escitalopram (Lexapro), which has received FDA approval for the treatment of anxiety, in 5 mg capsules.” NCT02516332 ↗ “Escitalopram (Lexapro) 5mg daily for first 2 weeks, and then 10 mg daily for 8 weeks versus Placebo for 10 weeks” NCT02153567 ↗ “the SSRI escitalopram (Lexapro), with the most recently available SNRI, duloxetine” NCT00215228 ↗ “Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)” NCT00200902 ↗ “This medication is called Lexapro (Escitalopram).” NCT01398514 ↗ “escitalopram (Lexapro and others)” NCT01944657 ↗ “escitalopram (Lexapro®) tablets” NCT03538691 ↗ “Escitalopram (Lexapro)5-30;” NCT00074815 ↗ “Escitalopram (Lexapro)” NCT00797966 ↗ “Escitalopram : Lexapro” NCT00935246 ↗ “Escitalopram (Lexapro)” NCT00156325 ↗ “Escitalopram (Lexapro)” NCT00260624 ↗ “Escitalopram (Lexapro)” NCT00277108 ↗ “escitalopram (Lexapro)” NCT00423969 ↗ “Escitalopram (Lexapro)” NCT06692361 ↗ |
| Known as | Lexapro (escitalopram) | “Lexapro (escitalopram)” NCT00642694 ↗1“Lexapro (escitalopram)” NCT00754793 ↗ |
| Known as | LU 26-054-0 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1508 ↗ |
| Known as | LU-26-054 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1508 ↗ |
| Known as | LU-26-054-O | ChEMBL registry synonym — accepted as the source's own label CHEMBL1508 ↗ |
| Known as | NSC-758934 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1508 ↗ |
| Known as | Reconter | “Escitalopram oxalate (Reconter), 10mg/day (first 3 weeks) and 20mg/day (week 3 to week 10).” NCT01894815 ↗ |
| Known as | S-citalopram | “effect of an antidepressive pre-treatment over two weeks and a continuously concomitant treatment with Escitalopram (S-citalopram) on frequency and severity of depression” NCT00136318 ↗ |
| Known as | SCIT | “To define these subtypes, a prospectively-treated cohort of 100 patients will be randomized to receive either escitalopram (s-CIT) or CBT for the first 12 weeks, with...” NCT00367341 ↗2“Subjects will be randomized to receive either escitalopram (s-CIT) or CBT for 12 weeks.” NCT02137369 ↗ “Escitalopram (SCIT) is frequently prescribed to breastfeeding women.” PMID 32162723 ↗ Apr 2020 |
| Known as | Seroplex | “Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,” NCT01962753 ↗ |
| Action | Inhibit | “a selective serotonin reuptake inhibitor” NCT00070941 ↗1“Serotonin transporter inhibitor” CHEMBL1508 ↗ |
| Modality | Small molecule | “Escitalopram (an SSRI-compound)” NCT00971815 ↗ |
| Route | Oral | “40 subjects receiving oral escitalopram 20mg or 40 mg daily, in two divided doses, and placebo SAM-e.” NCT00070941 ↗ |
| Target | CYP2D6 | “It is stated that escitalopram is only a weak inhibitor of CYP2D6” NCT00692263 ↗ |
| Target | SLC6A4 | “Serotonin transporter inhibitor” CHEMBL1508 ↗ |